Rocket Pharmaceuticals initiated with an Outperform at William Blair. William Blair analyst Raju Prasad started Rocket Pharmaceuticals with an Outperform rating. Rocket is a “multi-platform gene therapy company ready for launch” with up to four clinical programs in 2019, the analyst contends
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.